Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04736472 · ClinicalTrials.gov registry record · NA
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 552
- Enrollment target
NCT04736472: Completed NA study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT04736472 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 552 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04736472, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 552 participants
- Enrollment target
Study Summary
Pharmacogenomics (PGx) is the study of how genes affect a person's response to drugs. PGx testing for certain genes can help predict the risk of side effects from chemotherapy agents. Testing is not regularly performed in clinical practice due to long wait times for results and challenges with integrating test results in the electronic health record. Investigators leading this study hope to find out if providing cancer care providers with the ability to order a PGx test and electronically receive results with dosing recommendations will increase the use of these tests to guide treatment decisions and improve patient outcomes. This is a non-randomized implementation study, which means that all participants in this study will undergo genotyping for a pharmacogenetic test. The investigators will primarily measure the feasibility of using this test to guide cancer care.
Primary Outcome
The Number and percentage of participants who had their pharmacogenetic tests returned prior to the first determined dose of chemotherapy.
Interventions
- DEVICE Pharmacogenetic test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2021-03-26 |
| Est. Completion | 2024-10-09 |
| Phase | NA |
What the finished NCT04736472 record still lists
NCT04736472 is an interventional study that assigns participants to a tested intervention. The registered 552 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 1 intervention - of which Pharmacogenetic test is the first listed.
NCT04736472 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04736472 about?
NCT04736472 is a clinical study titled "Implementing Pharmacogenetic Testing in Gastrointestinal Cancers". Pharmacogenomics (PGx) is the study of how genes affect a person's response to drugs. PGx testing for certain genes can help predict the risk of side effects from chemotherapy agents. Testing is not regularly performed in clinical practice due to long wait times for results and challenges with integ...
What is the current status of trial NCT04736472?
This trial is currently completed. It is a NA study. The enrollment target is 552 participants. The study started on 2021-03-26. Estimated completion is 2024-10-09.
What interventions are being tested in trial NCT04736472?
The interventions under investigation include: Pharmacogenetic test (DEVICE).
Who is sponsoring clinical trial NCT04736472?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04736472's enrollment target sits among peer trials
552 184th of 2000 higher than 1,817 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI